KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Novavax (NVAX) over the last 13 years, with Q3 2025 value amounting to $138.3 million.

  • Novavax's Other Accumulated Expenses fell 5089.58% to $138.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $138.3 million, marking a year-over-year decrease of 5089.58%. This contributed to the annual value of $219.6 million for FY2024, which is 7450.73% down from last year.
  • Per Novavax's latest filing, its Other Accumulated Expenses stood at $138.3 million for Q3 2025, which was down 5089.58% from $132.5 million recorded in Q2 2025.
  • Novavax's 5-year Other Accumulated Expenses high stood at $930.1 million for Q4 2022, and its period low was $2.4 million during Q1 2021.
  • Its 5-year average for Other Accumulated Expenses is $312.5 million, with a median of $160.5 million in 2022.
  • Per our database at Business Quant, Novavax's Other Accumulated Expenses surged by 431295.02% in 2022 and then crashed by 7450.73% in 2024.
  • Over the past 5 years, Novavax's Other Accumulated Expenses (Quarter) stood at $36.1 million in 2021, then soared by 2479.12% to $930.1 million in 2022, then fell by 7.38% to $861.4 million in 2023, then tumbled by 74.51% to $219.6 million in 2024, then tumbled by 37.01% to $138.3 million in 2025.
  • Its Other Accumulated Expenses was $138.3 million in Q3 2025, compared to $132.5 million in Q2 2025 and $142.0 million in Q1 2025.